The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

Bone Marrow Transplantation

Volumn 46, Issue 3, 2011, Pages 356-363

  D'Addio, A ^a   Curti, A ^a   Worel, N ^b   Douglas, K ^c   Motta, M R ^a   Rizzi, S ^a   Dan, E ^a   Taioli, S ^a   Giudice, V ^d   Agis, H ^b   Kopetzky, G ^e   Soutar, R ^c   Casadei, B ^a   Baccarani, M ^a   Lemoli, R M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e GENERAL HOSPITAL   (Austria)

Author keywords

autologous stem cell transplantation; PBSC mobilization; plerixafor; poor mobilizers

Indexed keywords

BENDAMUSTINE; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PLERIXAFOR; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CD34 SELECTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; IMMUNOTHERAPY; LEUKAPHERESIS; LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; SALVAGE THERAPY; STEM CELL MOBILIZATION;

ADULT; AGED; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS;

EID: 79952535006     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.128     Document Type: Article

References (38)

1. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502. (Pubitemid 38010075)
2. Erratum in: NEngl JMed2004; 350(25):2628.
3. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garc?a-Conde J et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395-1404. (Pubitemid 32202546)
4. Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77: 1587-1592.
5. + cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967-972. (Pubitemid 34845951)
6. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181-195.
7. Lemoli RM, D'Addio A. Hematopoietic stem cell mobiliza-tion. Haematologica 2008; 93: 321-324.
8. + hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004; 1: 165-172.
9. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095-1102. (Pubitemid 41095043)
10. + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-338. (Pubitemid 351330727)
11. Dipersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granu-locyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
12. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for auto-logous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
13. Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamaki E, Remes K et al. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347-351. (Pubitemid 36410680)
14. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225-231. (Pubitemid 40293285)
15. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47.
16. Hussein MA, Bolejack V, Zonder JA, Durie BG, Jakubowiak AJ, Crowley JJ et al. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a south-west oncology group trial (S0204). J Clin Oncol 2009; 27: 3510-3517.
17. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009; 23: 449-456.
18. Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E et al. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term? Haematologica 1999; 84: 996-1001.
19. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242. (Pubitemid 34438862)
20. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Vitolo U et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 2008; 112: 856-862. (Pubitemid 351246571)
21. Brusamolino E, Bacigalupo A, Barosi G, Biti G, Gobbi PG, Levis A et al. Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experi-mental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica 2009; 94: 550-565.
22. Bishton MJ, Lush RJ, Byrne JL, Russell NH, Shaw BE, Haynes AP. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007; 136: 752-761.
23. Hagberg H, Gisselbrecht C CORAL study group. Rando-mised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006; 17(Suppl 4): iv31-iv32. (Pubitemid 43778973)
24. Weide R, Hess G, Koppler H, Heymanns J, Thomalla J, Aldaoud A et al. High anti-lymphoma activity of bendamus-tine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48: 1299-1306. (Pubitemid 47082223)
25. Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lym-phoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23: 9208-9218.
26. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) signifi-cantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-3071. (Pubitemid 39517009)
27. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 2008; 49: 1074-1080 (Pubitemid 351943252)
28. Mart?n A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008; 93: 1829-1836.
29. + cells in multiple myeloma. Ann Hematol 2001; 80: 592-597. (Pubitemid 33061999)
30. + cells in elderly patients (?70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413-423. (Pubitemid 36241497)
31. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 1729-1735.
32. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23: 1904-1912.
33. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042. (Pubitemid 47299979)
34. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2007; 22: 1280-1281.
35. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718-723.
36. Kuittinen T, Nousiainen T, Halonen P, Mahlamaki E, Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907-912. (Pubitemid 38660123)
37. Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omede P et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 2002; 30: 725-732. (Pubitemid 36007752)
38. Douglas K, Hayden P, Rahemtulla A, DAddio A, Rao K, Maris M et al. Plerixafor for PBSC mobilization in myeloma patients with advanced renal failure: safety and efficacy data in a series of 12 patients from the US or European Compassio-nate Use Programmes and from the US post-licensing. Bone Marrow Transplant 2010; 45(Suppl.2): S3-S23.